General Information of This Drug (ID: DM7TOWX)

Drug Name
ABT-333   DM7TOWX
Synonyms
Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; ABT333; UNII-DE54EQW8T1; ABT 333; Dasabuvir (ABT-333); DE54EQW8T1; CHEBI:85182; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; Dasabuvir [USAN:INN]; Dasabuvir (USA
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Paritaprevir + ABT-333 DCEUHY4 Paritaprevir Chronic Hepatitis C [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
2 ClinicalTrials.gov (NCT01464827) ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients